"Mutation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Descriptor ID |
D009154
|
MeSH Number(s) |
G05.365.590
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mutation".
Below are MeSH descriptors whose meaning is more specific than "Mutation".
This graph shows the total number of publications written about "Mutation" by people in this website by year, and whether "Mutation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 15 | 26 | 41 |
1996 | 24 | 22 | 46 |
1997 | 26 | 16 | 42 |
1998 | 23 | 37 | 60 |
1999 | 14 | 34 | 48 |
2000 | 27 | 41 | 68 |
2001 | 15 | 48 | 63 |
2002 | 21 | 49 | 70 |
2003 | 20 | 76 | 96 |
2004 | 19 | 61 | 80 |
2005 | 23 | 80 | 103 |
2006 | 25 | 72 | 97 |
2007 | 27 | 56 | 83 |
2008 | 25 | 67 | 92 |
2009 | 25 | 69 | 94 |
2010 | 34 | 66 | 100 |
2011 | 35 | 83 | 118 |
2012 | 45 | 69 | 114 |
2013 | 42 | 68 | 110 |
2014 | 44 | 80 | 124 |
2015 | 47 | 88 | 135 |
2016 | 39 | 93 | 132 |
2017 | 34 | 77 | 111 |
2018 | 42 | 105 | 147 |
2019 | 48 | 68 | 116 |
2020 | 37 | 92 | 129 |
2021 | 25 | 84 | 109 |
2022 | 8 | 80 | 88 |
2023 | 2 | 84 | 86 |
2024 | 29 | 59 | 88 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mutation" by people in Profiles.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Conformational coupling between extracellular and transmembrane domains modulates holo-adhesion GPCR function. Nat Commun. 2024 Dec 04; 15(1):10545.
-
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Dec 02; 30(23):5445-5458.
-
Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy. Arch Pathol Lab Med. 2024 Dec 01; 148(12):1310-1319.
-
A sodium channel mutant removes fast inactivation with the inactivation particle bound. J Gen Physiol. 2025 01 06; 157(1).
-
Constitutive opening of the Kv7.2 pore activation gate causes KCNQ2-developmental encephalopathy. Proc Natl Acad Sci U S A. 2024 Dec 03; 121(49):e2412388121.
-
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms. Blood Adv. 2024 Nov 26; 8(22):5796-5805.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 Nov 19; 14(1):202.
-
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nat Cancer. 2024 Dec; 5(12):1885-1901.